Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 5
- Sponsors Novo Nordisk
- 31 May 2023 Results of a post-hoc analysis from clinical trials: PIONEER 1-5 and 8 assessing clinically relevant composite endpoints of HbA1c (glyclated haemogloblin) reduction published in the Diabetes Therapy
- 29 Jun 2021 Data from PIONEER 1-5, 7 AND 8 were used to assess BW loss, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 17 May 2021 Results of a pooled analysis of data from SUSTAIN 3 and PIONEER 1, 2, 5 studies assessing the effect of the two formulations of semaglutide vs comparators on hsCRP (an anti-inflammatory marker) presented at the 70th Annual Scientific Session of the American College of Cardiology